% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Pulte:132852,
author = {D. Pulte$^*$ and L. Jansen$^*$ and H. Brenner$^*$},
title = {{D}isparities in {C}olon {C}ancer {S}urvival by {I}nsurance
{T}ype: {A} {P}opulation-{B}ased {A}nalysis.},
journal = {Diseases of the colon $\&$ rectum},
volume = {61},
number = {5},
issn = {0012-3706},
address = {Hagerstown, Md.},
publisher = {Lippincott Williams $\&$ Wilkins},
reportid = {DKFZ-2018-00495},
pages = {538 - 546},
year = {2018},
abstract = {Colon cancer is a common cancer with a relatively high
survival for nonmetastatic disease if appropriate treatment
is given. A lower survival rate for patients with no or
inadequate insurance has previously been documented, but the
differences have not been explored in detail on a population
level.The purpose of this study was to examine survival for
patients with colon cancer by insurance type.Complete
analysis was used to examine 1-, 2-, and 3-year survival
rates.This was a population-level analysis.Patients were
drawn from the in-patients diagnosed with colon cancer at
ages 15 to 64 years between 2007 and 2012 in the
Surveillance, Epidemiology, and End Results 18 database by
insurance type (Medicaid, uninsured, or other insurance)
MAIN OUTCOME MEASURE:: This study measured overall
survival.A total of 57,790 cases were included, with
insurance information available for 55,432. Of those, 7611
$(13.7\%),$ 4131 $(7.5\%),$ and 43,690 $(78.8\%)$ had
Medicaid, no insurance, or other insurance. Patients with
Medicaid or without insurance were more likely to have
metastatic disease compared with those with other insurance.
Survival was higher for patients with insurance other than
Medicaid, with 3-year survival estimates of $57.0\%,$
$61.2\%,$ and $75.6\%$ for Medicaid, uninsured, and other
insurance. Significant disparities continued to be observed
after adjustment for stage, especially for later-stage
disease. When only patients with stage I to II disease who
had definitive surgery and resection of ≥12 lymph nodes
were included in the analysis, the discrepancy was
decreased, especially for uninsured patients.Information on
chemotherapy use and biological markers of disease severity
are not available in the database.Colon cancer survival is
lower for patients with no insurance or with Medicaid than
for those with private insurance. Differences in rates of
definitive surgery and adequate lymph node dissection
explain some of this disparity. See Video Abstract at
http://links.lww.com/DCR/A585.},
cin = {C070 / G110 / L101},
ddc = {150},
cid = {I:(DE-He78)C070-20160331 / I:(DE-He78)G110-20160331 /
I:(DE-He78)L101-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29624548},
doi = {10.1097/DCR.0000000000001068},
url = {https://inrepo02.dkfz.de/record/132852},
}